Icon to slash costs amid pandemic as 65% of its trial sites disrupted by COVID-19

As CROs report their first-quarter financials, Icon has issued some grim warnings about how much COVID-19 and the resultant lockdowns are hitting its business.

The company said it started to feel the hit from the pandemic back in February at its China trial sites (where the pandemic first started). But now, it is starting to feel the bite elsewhere as the virus spreads rapidly across the globe, saying the hit is “prevalent in our clinical business with approximately 65% of our global sites impacted in some way by the pandemic.”